Year: 2023
Type: review
Abstract: The progression of cancer involves a critical step in which malignant cells escape from control by the immune system. Antineoplastic agents are particularly efficient when they succeed in restoring such control (immunosurveillance) or at least establish an equilibrium state that slows down disease progression. This is true not only for immunotherapies, such as immune checkpoint inhibitors (ICIs), but also for conventional chemotherapy, targeted anticancer agents, and radiation therapy. Thus, therapeutics that stress and kill cancer cells while provoking a tumor-targeting immune response, referred to as immunogenic cell death, are particularly useful in combination with ICIs. Modern oncology regimens are increasingly using such combinations, which are referred to as chemoimmunotherapy, as well as combinations of multiple ICIs. However, the latter are generally associated with severe side effects compared with single-agent ICIs. Of note, the success of these combinatorial strategies against locally advanced or metastatic cancers is now spurring successful attempts to move them past the postoperative (adjuvant) setting to the preoperative (neoadjuvant) setting, even for patients with operable cancers. Here, the authors critically discuss the importance of immunosurveillance in modern clinical cancer management.
DOI: 10.3322/caac.21818
Institutions: Inserm, Institut Universitaire de France, Université Paris Cité, Institut Gustave Roussy, Sorbonne Université, Centre de Recherche des Cordeliers, La Ligue Contre le Cancer, Hôpital Européen Georges-Pompidou, Cleveland Clinic, Case Comprehensive Cancer Center, University Medical Center Utrecht, Princess Máxima Center, Technical University of Munich, Ludwig-Maximilians-Universität München, Weill Cornell Medicine
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,330
Funders: Starr Cancer Consortium, U.S. Department of Defense, Bristol-Myers Squibb, Pfizer, AstraZeneca, Sanofi, Leukemia and Lymphoma Society, Association pour la Recherche sur le Cancer, Les Laboratories Pierre Fabre, Seerave Foundation, Equipex, Incyte, Galecto, SkylineDx, European Commission, Agence Nationale de la Recherche, Fondation pour la Recherche Médicale, Eisai, Ligue Contre le Cancer, Centre National de la Recherche Scientifique, Institut Universitaire de France, Institut National Du Cancer, Université de Paris, National Institutes of Health, U.S. Food and Drug Administration, Weill Cornell Medical College, Stand Up To Cancer, Labex Immuno-Oncology, National Cancer Institute, Daiichi Sankyo Europe
Awards: G1056382719, G1064932160, G1152389130, G1168482666, G1397743473, G1462752421, Next-generation phenotypic screening for oncological applications, G1716190585, G1846858737, G1963894250, THERAPEUTIC TARGETING OF BREAST CANCER AND HOST IMMUNE RESPONSES AT INFLECTION POINTS IN THE DISEASE TRAJECTORY, G2161503289, Lung cancer prevention and interception, Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception., G2351262490, G2669570515, G2699422577, G2776565293, G2786066923, G282393413, G2877016160, G3049070650, G3116448791, Mitochondrial copper targeting to modulate inflammatory macrophages, G330243840, G3500543458, Elucidating genetics of response to immune checkpoint blockade in lung cancer, G3599999703, G3853421405, G4007257112, G434337789, G4656594441, G4707887143, G4950536974, Microbiota-centered interventions to solve antibiotics-induced primary resistance to immune checkpoint inhibitors, G5468290041, Energizing the failing heart, G5790172013, G5851709705, G5868422650, G5946283803, G6292965458, Towards Precision Immuno-Oncology: Unraveling the Genomic Determinants and Mechanisms Underlying Immunotherapy Efficacy and Resistance, G668953012, G7185013638, G7319818416, G82931992, G8460343049, Université de Paris, The RUSH (retention using selective hooks) system: a chemical-genetic system for the in vivo manipulation of intercellular communication, Dynamics of Immune Response in Irradiated Rectal Cancer, Targeting the BCL2 immune checkpoint to enhance the immunostimulatory effects of radiation in breast cancer, Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies
OpenAlex ID: W4387948813